Industry Focus

An infant participating in Novartis' Zolgensma trial has died, raising questions ahead of an expected FDA decision next month for this one-and-done treatment for spinal muscular atrophy. Here's what you should know. Also, why investors should ignore Intuitive Surgical's first quarter earnings miss and buy shares on sale.

Check out more of our content here:

Direct download: 20190424_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT